CNETS NEWS

COVID-19 VACCINE & NEUROENDOCRINE CANCER PATIENTS

March 19th, 2021|Comments Off on COVID-19 VACCINE & NEUROENDOCRINE CANCER PATIENTS

Disclaimer: CNETS is a patient organization, and we are unable to provide medical advice. Any information or guidance contained herein should not replace personalized medical advice. Our objective is to provide you with general [...]

LUTATHERA Funded In British Columbia

March 8th, 2021|Comments Off on LUTATHERA Funded In British Columbia

CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication. The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal Peptide Receptor Radionuclide Therapy (PRRT) using [...]

INSPIRATIONAL NET CANCER PATIENT STORY

February 11th, 2021|Comments Off on INSPIRATIONAL NET CANCER PATIENT STORY

INSPIRATIONAL NEUROENDOCRINE CANCER PATIENT STORY Long-time CNETS fundraisers Bryde Fresque and Natalie Mezey, share a message of hope! As outlined in this Ottawa Hospital Foundation report, Bryde Fresque was diagnosed with a rare [...]

ESMO Guidelines: Lung & Thymic Carcinoids

February 4th, 2021|Comments Off on ESMO Guidelines: Lung & Thymic Carcinoids

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Published January 19, 2021 Highlights This updated ESMO Clinical Practice Guideline provides key recommendations on the [...]

European Journal of Cancer Article

January 5th, 2021|Comments Off on European Journal of Cancer Article

Article: Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era February 2021 - European Journal of Cancer, Review Article on  "Practical recommendations for [...]

INCA NETInfo

December 26th, 2020|Comments Off on INCA NETInfo

INCA GLOBAL NET PATIENT INFO PACK NEW FOR 2020! - NETInfo INCA launches a range of factsheets on NETs that are free to download. These factsheets provide comprehensive information on NETs and [...]

LUTATHERA® Funded in Ontario

October 10th, 2020|Comments Off on LUTATHERA® Funded in Ontario

Radiopharmaceutical cancer treatment Lutathera® now available to Ontario patients with midgut neuroendocrine tumours (NETs). The Ontario funding criteria covers the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut NETs whose disease has progressed on [...]

LUTATHERA® Funded in Quebec

October 3rd, 2020|Comments Off on LUTATHERA® Funded in Quebec

As of September 30, 2020, the Québec Ministry of Health and Social Services has listed Lutathera on the Liste de Médicaments – Établissements. Lutathera will be reimbursed for GEP-NETs patients with advanced disease that is [...]

LUTATHERA® Funded in Nova Scotia

September 4th, 2020|Comments Off on LUTATHERA® Funded in Nova Scotia

As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut NETs whose disease has progressed [...]